Key Takeaways
- • Activist investor Jonathan Litt, via his hedge fund Land & Buildings Investment Holdings, has established a short position on Alexandria Real Estate Equities (ARE), arguing the life sciences REIT faces structural headwinds similar to traditional office space despite market positioning to the contrary.
- • Litt asserts that approximately 20% of new life sciences space is coming to market, compounded by rising vacancy rates, potentially depressing Alexandria's valuations by as much as 40% if the portfolio were valued using office REIT multiples.
- • Land & Buildings' white paper data shows mobile phone presence in Alexandria's portfolio declined roughly 50% compared to pre-pandemic levels, suggesting significant underutilization of the company's life sciences assets.
- • Alexandria Executive Chairman Joel Marcus rejected Litt's thesis, distinguishing life sciences real estate from secular-decline office space and citing the $4T–$5T life sciences industry as a fundamental demand driver backed by recent lease signings.
- • Alexandria recently divested a five-building Boston-area campus and has decelerated project development, signaling market pressures the company is navigating amid the debate over sector fundamentals.
Summary
Activist investor Jonathan Litt has launched a public short campaign against Alexandria Real Estate Equities, the nation's largest life sciences real estate income trust, arguing that the sector faces structural challenges mirroring the broader commercial office downturn. Speaking on CNBC on Thursday, Litt stated: "Alexandria has got a real problem. There's about 20% of new space coming on the market, which is on top of likely increasing vacancies." His hedge fund, Land & Buildings Investment Holdings, holds a confirmed short position on the REIT.
Litt's central thesis contends that life sciences valuations are artificially inflated and would decline by as much as 40% if subjected to the valuation multiples applied to traditional office REITs. To support this argument, Land & Buildings released a white paper on Friday documenting a 50% decline in mobile phone presence across Alexandria's portfolio compared to pre-pandemic levels—a metric the firm uses as a proxy for asset utilization and occupancy density.
Alexandria's leadership has disputed this characterization, with Executive Chairman Joel Marcus directly refuting the office-space comparison. "Life science is not office space," Marcus told Bisnow. "You can't in any way, shape or form associate it with generic office, which is, in fact, in secular decline." Marcus emphasized that the life sciences sector, valued at $4T–$5T globally, maintains structural demand for specialized laboratory and research space, citing recent lease signings as evidence of underlying tenant appetite.
The dispute reflects broader market concerns about life sciences real estate sector fundamentals. Alexandria has slowed development progress and executed a significant divestiture this week, selling a five-building Boston-area campus, indicating management's own adjustment to market conditions. These actions, coupled with the upcoming renewal of major leases in the company's portfolio, suggest the sector is entering a period of valuation pressure and potential repricing regardless of its ultimate classification as distinct from traditional office markets.
Litt's central thesis contends that life sciences valuations are artificially inflated and would decline by as much as 40% if subjected to the valuation multiples applied to traditional office REITs. To support this argument, Land & Buildings released a white paper on Friday documenting a 50% decline in mobile phone presence across Alexandria's portfolio compared to pre-pandemic levels—a metric the firm uses as a proxy for asset utilization and occupancy density.
Alexandria's leadership has disputed this characterization, with Executive Chairman Joel Marcus directly refuting the office-space comparison. "Life science is not office space," Marcus told Bisnow. "You can't in any way, shape or form associate it with generic office, which is, in fact, in secular decline." Marcus emphasized that the life sciences sector, valued at $4T–$5T globally, maintains structural demand for specialized laboratory and research space, citing recent lease signings as evidence of underlying tenant appetite.
The dispute reflects broader market concerns about life sciences real estate sector fundamentals. Alexandria has slowed development progress and executed a significant divestiture this week, selling a five-building Boston-area campus, indicating management's own adjustment to market conditions. These actions, coupled with the upcoming renewal of major leases in the company's portfolio, suggest the sector is entering a period of valuation pressure and potential repricing regardless of its ultimate classification as distinct from traditional office markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.